olodaterol + BI54903

Olodaterol + BI54903 is an experimental fixed-dose combination of two small molecule drugs intended for inhalation therapy in respiratory diseases. **Olodaterol** is a long-acting beta2-adrenergic agonist (LABA) that acts by selectively activating beta2-adrenergic receptors in lung airway smooth muscle, resulting in bronchodilation and prolonged improvement in lung function, especially in chronic obstructive pulmonary disease (COPD)[1]. **BI54903** is a glucocorticoid receptor agonist developed by Boehringer Ingelheim for potential anti-inflammatory effects; it binds and activates the glucocorticoid receptor, modulating gene transcription to suppress airway inflammation[2]. The combination was designed to provide both bronchodilation and anti-inflammatory effects for asthma and potentially other obstructive airway diseases, but clinical development was discontinued[2].

Brand names

Striverdi Respimat

Other names

olodaterol + BI54903